NCT01937442View on ClinicalTrials.gov

Pharmacokinetic Study of Thalidomide in Subjects With Multiple Myeloma

PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

November 7, 2013

Primary Completion Date

September 23, 2015

Study Completion Date

September 23, 2015

Conditions
Multiple Myeloma
Interventions
DRUG

Thalidomide Celgene™

200mg once daily and by mouth

Trial Locations (7)

29609

Hopital Augustin Morvan, Brest

37044

CHRU Hopital Bretonneau, Tours

38043

CHU Grenoble, Grenoble

54511

CHRU Hopital Brabois, Vandœuvre-lès-Nancy

59037

CHRU-Hopital Claude Huriez, Lille

M20 4BX

Christie Hospital NHS Foundation Trust, Manchester

SM2 5PT

Royal Marsden Hospital, Sutton

Sponsors

Lead Sponsor

Celgene
All Listed Sponsors
lead

Celgene

INDUSTRY

NCT01937442 - Pharmacokinetic Study of Thalidomide in Subjects With Multiple Myeloma | Biotech Hunter | Biotech Hunter